Rick Yang Purchases 207,100 Shares of Korro Bio (NASDAQ:KRRO) Stock

Korro Bio, Inc. (NASDAQ:KRRO) major shareholder Rick Yang purchased 207,100 shares of Korro Bio stock in a transaction dated Tuesday, March 10th. The shares were purchased at an average price of $11.11 per share, with a total value of $2,300,881.00. Following the completion of the acquisition, the insider owned 1,297,893 shares in the company, valued at $14,419,591.23. The trade was a 18.99% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Korro Bio Stock Performance

Shares of NASDAQ KRRO opened at $12.80 on Friday. The business has a 50 day simple moving average of $10.99 and a 200 day simple moving average of $20.18. Korro Bio, Inc. has a 52 week low of $5.20 and a 52 week high of $55.89. The stock has a market cap of $120.58 million, a price-to-earnings ratio of -1.03 and a beta of 2.98.

Korro Bio (NASDAQ:KRRO) last issued its quarterly earnings data on Thursday, March 12th. The company reported ($5.32) earnings per share for the quarter, missing the consensus estimate of ($1.93) by ($3.39). The business had revenue of $1.29 million for the quarter, compared to the consensus estimate of $0.43 million. Korro Bio had a negative net margin of 1,834.48% and a negative return on equity of 99.63%. On average, analysts predict that Korro Bio, Inc. will post -9.52 EPS for the current year.

Key Headlines Impacting Korro Bio

Here are the key news stories impacting Korro Bio this week:

• Positive Sentiment: Raymond James upgraded KRRO from “market perform” to “outperform” and set a $23 price target, providing a prominent analyst endorsement that can attract momentum and institutional buyers. Read More.
• Positive Sentiment: Multiple major shareholders and investors (including Enterprise Associates/NEA‑17, Forest Baskett, Scott Sandell and others) disclosed large purchases (~207,100 shares at ~$11.11 each), signaling strong insider/large‑holder conviction and providing buying support. Read More.
• Positive Sentiment: Corporate update: Korro nominated KRRO‑121 for hyperammonemia, is advancing a GalNAc oligo candidate for AAT deficiency (on track to nominate in Q2 2026), and closed an oversubscribed $85M private placement, which management says extends cash runway into H2 2028 — materially reducing near‑term financing risk. Read More.
• Neutral Sentiment: Revenue for Q4 modestly exceeded expectations ($1.29M vs. ~ $0.42M est.), but the amount is very small relative to R&D and operating burn, so near‑term profit improvement is limited. Read More.
• Negative Sentiment: Quarterly and annual results show heavy write‑downs and operating losses: Q4 EPS was a ($5.32) miss vs. consensus (~($1.93)), and full‑year net loss widened (reported ~$117.3M) driven by non‑cash impairment charges — highlighting high execution risk and potential for volatility if clinical progress stalls. Read More. Read More.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on KRRO shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Korro Bio in a research report on Friday, January 9th. Raymond James Financial upgraded Korro Bio from a “market perform” rating to an “outperform” rating and set a $23.00 price target for the company in a research note on Friday. Wall Street Zen lowered Korro Bio from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. Chardan Capital raised Korro Bio from a “neutral” rating to a “buy” rating and set a $15.00 price objective on the stock in a research note on Thursday, January 29th. Finally, JonesTrading lowered Korro Bio from a “buy” rating to a “hold” rating in a report on Friday, November 14th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Korro Bio has a consensus rating of “Moderate Buy” and an average target price of $44.50.

Institutional Investors Weigh In On Korro Bio

A number of hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC grew its position in shares of Korro Bio by 10.8% in the second quarter. Geode Capital Management LLC now owns 155,387 shares of the company’s stock valued at $1,941,000 after purchasing an additional 15,166 shares during the last quarter. Raymond James Financial Inc. boosted its stake in Korro Bio by 357.6% during the 2nd quarter. Raymond James Financial Inc. now owns 83,392 shares of the company’s stock valued at $1,042,000 after purchasing an additional 65,170 shares during the period. Bank of America Corp DE boosted its stake in Korro Bio by 520.0% during the 2nd quarter. Bank of America Corp DE now owns 28,156 shares of the company’s stock valued at $352,000 after purchasing an additional 23,615 shares during the period. CWM LLC grew its holdings in Korro Bio by 391.4% in the 3rd quarter. CWM LLC now owns 2,693 shares of the company’s stock valued at $129,000 after buying an additional 2,145 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust bought a new position in Korro Bio in the 3rd quarter worth approximately $2,821,000. 13.18% of the stock is currently owned by institutional investors.

Korro Bio Company Profile

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.